All In Biotech

Drug Trial Radar · NCT06505395

A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)

A Phase Ⅱ Randomized, Parallel-group, Open-label, Active-controlled Trial to Assess the Efficacy, Safety and Pharmacokinetics of the Long-acting Octreotide Subcutaneous Injection (SYHX2008) Versus Octreotide Microspheres (Sandostatin LAR@) in Patients With GEP-NET

Last checked: Nov 20, 2026Latest source record: Aug 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Jul 30, 2024

Primary completion

Aug 1, 2027

Study completion Aug 1, 2028

Sponsor

Sponsor type
Industry
First posted
Jul 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the effectiveness, safety, pharmacokinetics (PK) of SYHX2008 vs Octreotide Microspheres (Sandostatin LAR@) in patients with advanced, well-differentiated GEP-NET.

Conditions

  • Gastrointestinal Neuroendocrine Pancreatic Tumor

Interventions

  • SYHX2008 injectionDrug

    The patients will accept SYHX2008 injection by subcutaneous administration every cycle.

  • Sandostatin LAR@Drug

    The patients will accept Sandostatin LAR@ by intra-muscular administration every cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) as assessed by a Blinded Independent Review Committee (BIRC)Time frame: Up to 1 years following the last patient enrolled

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chinese PLA General Hosptial

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.